Skip to content
DataLookout
Menu

ProTIPNCT06979492

Prophylactic Transfusion In Pregnant in Women With Sickle Cell Disease

StatusWithdrawn
PhasePhase 4
Primary completion (estimated)
Track this trial

Free. We email you which fields changed when ClinicalTrials.gov updates this record.

Record History

All 5 versions: 5 with changes below. See every version on ClinicalTrials.gov ↗

  1. Stopped Trial status changed: Recruiting → Withdrawn Sponsor's reason: The study was withdrawn due to no enrollment Show 7 more changesShow less
    • Enrollment target: estimated 50 to confirmed 0
    • Start date: Apr 2026 to Sep 2026
    • Eligibility criteria expanded, about 12 words
    • Primary endpoints: details revised at 1 of 5 entries
    • Trial arms changed: 2 → 3
    • Secondary endpoints: 11 to 12
    • Site details revised
  2. Notable Trial status: Not Yet Recruiting to Recruiting
    • Start date: Dec 2025 to Apr 2026
    • Site details revised
    v4
  3. Notable Start date: Aug 2025 to Dec 2025v3
  4. Notable Start date: Jun 2025 to Aug 2025
    • Primary endpoints revised (5)
    • Secondary endpoints revised (11)
    v2
  5. Study First Submitted
  • Stopped: terminated, suspended or withdrawn
  • Notable: the plan changed

Endpoints

Primary

Hospital admissions rate
Timeframe: Baseline (enrollment) up to 8 weeks post-partum
Number of maternal emergency department (ED)/Acute care visits
Timeframe: Baseline (enrollment) up to 8 weeks post-partum
Number of SCD-related complications per group
Timeframe: Baseline (enrollment) up to 8 weeks post-partum
Number of participants with pregnancy related complications
Timeframe: Baseline (enrollment) up to 8 weeks post-partum
Maternal death
Timeframe: From randomization up to 8 weeks post-partum

Secondary (12)

Adult Sickle Cell Quality of Life Measurement System (ASCQ-Me)
Patient reported outcomes measurement information system (PROMIS)
Infant birth weight
Preterm delivery
APGAR Scores
Show 7 moreShow less
Number of neonatal intensive care unit/critical care admissions
Perinatal death
Fetal demise/stillbirth
Number of participants with new RBC alloantibodies
Number of participants with transfusion reactions
Number of participants with an increase in iron overload (serum ferritin)
Number of participants with placental pathology

Arms and interventions

Standard of CareOther

Patients randomized to the control group will receive standard care for SCD alone. As part of the standard of care, women with SCD who become pregnant and who are on hydroxyurea (HU) will have the HU suspended by their primary SCD provider.

Red Blood Cell (RBC) TransfusionExperimental

Participants will receive a blood transfusion between 6 and 20 weeks of gestation. It will be repeated at 3-6 week intervals, aiming to maintain HbS \<30%

Normal health controlsNo intervention

Research testing on discarded, deidentified samples (placentas) of up to 10 women whose placentas were deemed normal, healthy, and full term by a clinical pathologist.

Biologicals: Prophylactic Transfusion Intervention group: Transfusion

Other: Control group

Sites

1 site in 1 country

  • Grady Health SystemAtlanta, Georgia, United States